Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same-day Biktarvy in Newly Diagnosed HIV
NCT04712058Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by National Taiwan University Hospital. Primary endpoints: Retention in care at Week 48 and Viral suppression (<50 copies/ml) at Week 48. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04712058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712058.